Your SlideShare is downloading. ×
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Parkinson’s Disease World Drug Industry 2014-2024
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Parkinson’s Disease World Drug Industry 2014-2024

730

Published on

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website …

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1195/Parkinson%27s-Disease-World-Drug-Industry-and-Market-2014-2024

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
730
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
13
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Parkinson’s Disease: World Drug Industry and Market 2014-2024 ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
  • 2. Contents 1. Executive Summary 1.1 Parkinson’s Disease Therapy: World Market Overview to 2024 1.2 Chapter Outlines 1.3 Research and Analysis Methods 2. Introduction to Parkinson’s Disease and its Treatments 2.1 What Causes Parkinson’s? 2.2 Motor Symptoms of Parkinson’s Disease 2.2.1 Tremor: The First Sign of PD 2.2.2 Uncontrolled Muscle Contractions Cause Rigidity 2.2.3 Bradykinesia: The Most Characteristic Feature of Parkinson’s 2.2.4 Postural Instability Manifests as PD Progresses 2.3 Neuropsychiatric Symptoms are Common in PD Patients 2.3.1 Behavioural Deficits are Often the Most Widespread 2.3.2 Cognitive Impairment Impede Daily Tasks 2.3.3 Autonomic Dysfunction: Another Common Occurrence 2.4 Other Symptoms Associated with Parkinson’s 2.5 Parkinson's Disease: Diagnosis and Treatment 2.5.1 Diagnosis is Difficult 2.5.2 Treatment Options – Therapeutic Classes 3. Parkinson’s Disease: World Drugs Market, 2014-2024 3.1 Sales of the Overall World PD Drugs Market, 2013-2024 3.2 Parkinson’s Disease: Market Segmentation, 2012 www.visiongain.com
  • 3. Contents 3.3 Overall PD Drug Market: Commercial Drivers and Restraints 3.4 Dopaminergic Agents: Foundation of PD Treatment 3.4.1 Levodopa Therapy 3.4.2 Patent Expiries Affect the Market 3.4.3 New Levodopa Therapies on the Horizon 3.4.4 Dopaminergic Agents: Market Projections to 2024 3.5 Dopamine Receptor Agonists: The Leading Class in 2013 3.5.1 Dopamine Agonists: A Front Line Drug 3.5.2 Advantages over L-Dopa Therapy 3.5.3 Leading Drugs in the Segment 3.5.4 Thin R&D Pipeline in That Segment 3.5.5 Dopamine Receptor Agonists: Market Projections, 2014-2024 3.6 Catechol-O-Methyl Transferase (COMT) Inhibitors: A Popular Choice of Treatment 3.6.1 Entacapone: The Leading Drug in this Segment 3.6.2 Commercial Scope for COMT Inhibitors 3.6.3 COMT Inhibitors: Market Projections, 2014-2024 3.7 Are Monoamine Oxidase–B (MAO-B) Inhibitors Better Than COMT? 3.7.1 MAO-B Inhibitor Therapeutics in the Market 3.7.2 New MAO-B Products in Development 3.7.3 MAO-B Inhibitors: Market Projections, 2014-2024 3.7.4 Other Mechanisms of Action: A Growing Opportunity 3.7.5 A Broad and Diverse Segment 3.7.5.1 Anticholinergics Therapeutics: The Oldest Class of PD Drugs 3.7.5.2 Glutamate Antagonists: Not A Popular Choice 3.7.6 Other Drugs in the Market www.visiongain.com
  • 4. Contents 3.7.7 The Pipeline Offers Disease Modifying Potential 3.7.8 Other Mechanisms of Action: Market Projections, 2014-2024 4. Leading Companies in the PD Drug Market, 2014 4.1 PD: The Most Important Therapy Area for Orion Pharmaceuticals 4.1.1 Market Forecast for Comtan/Stalevo, 2014-2024 4.2 Teva’s Azilect Continues to Grow 4.2.1 Market Forecast for Azilect, 2014-2024 4.3 UCB’s Leading Neupro Patch Drug 4.3.1 Market Forecast for Neupro, 2014-2024 4.4 Other Market Players 5. The Leading National Markets, 2014-2024 5.1 Regional Breakdown of the World PD Drug Market, 2012 5.2 The World PD Drug Market: Regional Forecasts to 2024 5.3 The PD Drug Market in the US: The Largest Single National Market 5.3.1 Market Projections for The US, 2014-2024 5.4 The PD Drug Market in the Five Leading European National Markets (EU5), 2014-2024 5.4.1 Market Projections for the EU5, 2014-2024 5.4.2 EU5 Breakdown by Country, 2012 5.4.3 Market Projection for EU5 Countries, Regional Breakdown 5.4.4 Germany: The Largest EU5 Market 5.4.4.1 Predictions for the German PD Drug Market, 2014-2024 5.4.5 France: Strong Healthcare System – What’s Possible There? 5.4.5.1 Predictions for the French PD Drug Market, 2014-2024 www.visiongain.com
  • 5. Contents 5.4.6 UK’s Spending Restrictions Affect the PD Drugs Market 5.4.6.1 Predictions for the UK PD Drug Market, 2014-2024 5.4.7 Spain – What Effects Will Austerity Have on PD Drug Sales? 5.4.7.1 Predictions for the Spanish PD Drug Market, 2014-2024 5.4.8 The PD Drug Market in Italy: Rising Ageing Population 5.4.8.1 Predictions for the Italian PD Drug Market, 2014-2024 5.5 Japan has the Highest Proportion of Over-65s in the World 5.5.1 Predictions for Japanese PD Drug Market, 2014-2024 5.6 PD Drug Market in Emerging Countries: Brazil, Russia, India and China (BRIC) 5.6.1 Breakdown of BRIC Revenues by Country, 2012 5.6.2 Market Projections for BRIC Nations’ PD Drug Sales, 2014-2024 5.6.3 Brazil’s Rapid Growth of the Pharma Market – What’s the Future? 5.6.4 Russia’s Growing Middle-Class Gives Pharma Sales Opportunities 5.6.5 India: Generic Manufacturers Seek to Dominate the PD Market 5.6.6 China’s Ageing Population Stimulates Sales of PD-Treating Medicines 6. Research and Development for Treating Parkinson’s Disease 6.1 New Mechanisms of Action in the Late-Stage R&D Pipeline 6.2 Growing Potential of Marketed Products: Phase IV Studies 6.3 Phase III Clinical Products Promising Potential in the PD market 6.3.1 Rytary (Impax Laboratories): The New Generation of Levodopa 6.3.1.1 Reformulations of Levodopa: Important Aspect of Therapy 6.3.2 Newron’s Safinamide Expected Launch in 2014 6.3.3 Pimavanserin: A First-in-Class Treatment for Parkinson's Disease Psychosis 6.3.4 Istradefylline: A Promising A(2a) Receptor Antagonist www.visiongain.com
  • 6. Contents 6.3.5 Termination of Preladenant, A Promising A(2a) Receptor Antagonist 6.3.6 Levodopa/Carbidopa Intestinal Gel (LCIG) 6.3.7 Can Opicapone Compete with Existing COMT Inhibitors 6.3.8 Pitolisant: Addressing an Unmet Need 6.3.9 Northera: Oral Precursor of Norepinephrine 6.3.10 Targin by Mundipharm 6.3.11 Nurelin for Levodopa-Induced Dyskinesia 6.3.12 SYN-115: Superior to Istradefylline? 6.4 Phase II PD Pipeline: Overview 6.4.1 Glutamatergic Drugs: Main Target for Pipeline Candidates 6.4.1.1 AFQ056 vs Dipraglurant 6.4.2 Fipamezole: Another Promising A(2a) Receptor Antagonist 6.4.3 CVT-301: A Novel Intrapulmonary Approach 6.4.4 DM-1992: Can Compete with Levodopa Reformulations? 6.4.5 The Accordion Pill Carbidopa/Levodopa by Intec Pharma 6.4.6 Orient Addresses Sialorrhoea 6.4.7 NH004: Formulated with a Muco-Adhesive Property 6.4.8 VR040: A Reformulation of Apomorphine 6.4.9 AVP-923: A Novel Approach for LID-PD 6.4.10 PD Giant Orion, Develop a New Levodopa Drug, ODM-101 6.4.11 News for NeuroDerm’s Reformulations 6.5 Phase I and Pre-clinical PD Pipeline: Overview 6.5.1 Vernalis’ A(2a) Receptor Antagonist Drug in Phase Ib/IIa 6.5.2 Sanofi Collaborates with The Michael J. Fox Foundation 6.5.3 UCL Show Exenatide Potential in Parkinson’s www.visiongain.com
  • 7. Contents 6.5.4 Titan Pharmaceuticals Develop a Novel Platform 6.6 Neuroprotective Drugs Offer Hope 6.6.1 Isradipine by The Parkinson Study Group 6.6.2 Phytopharm and Cogane Development 6.6.3 The Potential of Dietary Supplements 6.6.4 GCase Enzymes: Amicus and Biogen Strike A Deal for Parkinson’s 6.6.5 Research Finds Ursodeoxycholic Acid (UDCA) A Potential Cure for Parkinson’s 6.6.6 PD Biomarkers: Potential for Revolutionising Diagnosis and Treatment 6.6.7 Antibody Targeting: The Coming of Age 6.7 Gene Therapy: Promising Research and Technology 6.7.1 ProSavin: Leading Gene Therapy Product 6.7.2 CERE-120 Promises Repair of Damaged Dopaminergic Neurons 6.7.3 AAV-hAADC-2: Another Gene Therapy Contender 6.8 Parthenogenesis (International Stem Cell Corporation): A Promising Outlook for PD Technology 7. Qualitative Analysis of the PD Drug Market, 2014 7.1 SWOT Analysis of the PD Market 7.1.1 Strengths and Weaknesses in the PD Drug Industry in 2014 7.1.2 Opportunities and Threats There from 2014 Onwards 7.2 STEP Analysis of the PD Market 7.2.1 Social Implication of Living with PD 7.2.2 Technological Developments on the Horizon 7.2.3 Economic Pressures: Healthcare Budgeting 7.2.4 Political Issues: Patent Challenges, Data Exclusivity and Regulatory Pathways www.visiongain.com
  • 8. Contents 8. Research Interviews 8.1 Interview with Dr. Simon Craw, International Stem Cell Corporation, California, US 8.1.1 The Overall PD Market 8.1.2 Current Understanding of Stem Cell Therapy 8.1.3 ISCO’s Novel PD Programme 8.1.4 The Potential of Immune-Matching 8.1.5 The Controversy Surrounding Stem Cell Research 8.1.6 The Potential for Parthenogenesis in PD and Other Applications 8.2 Interview with Dr Neal Farber, CEO, NeuroHealing Pharmaceuticals, Massachusetts, US 8.2.1 Advantages of Anticholinergics over Current Treatment Methods 8.2.2 Application of NH004 In Other Neurological Diseases 8.2.3 Improving Quality of Life 9. Conclusions from the Research and Analysis 9.1 The World PD Medicines Market: Predictions to 2024 9.2 Which Drug Class will Dominate the Market in 2024? 9.3 Disease Modification: The Ultimate Goal 9.4 The Future of the Industry and Market for Parkinson’s Medicines Appendices About Visiongain’s Bespoke Research Service Appendix A: About Visiongain Appendix B: Visiongain Report Evaluation Form www.visiongain.com
  • 9. Contents List of Tables Table 1.1: Currency Exchange Rates, 2012 & 2013 Table 2.1 Overview of the Therapeutic Drug Classes for PD, 2014 Table 3.1 World Parkinson’s Disease Drug Market, Revenue ($m), AGR (%), CAGR (%), 20132018 Table 3.2 World Parkinson’s Disease Drug Market, Revenue ($m), AGR (%), CAGR (%), 20192024 Table 3.3 PD Market Segmentation, Revenues ($m), Market Shares (%), 2012 Table 3.4 PD Market Breakdown by Segment: Forecasts ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 3.5 PD Market Breakdown by Segment: Forecasts ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 3.6 Formulations of Levodopa Therapy, 2013 Table 3.7 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 3.8 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 3.9 Overview of Therapeutic Drug Classes in PD Therapy, 2014 Table 3.10 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 3.11 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 3.12 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 3.13 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 3.14 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR(%), Market Share (%), 2013-2018 www.visiongain.com
  • 10. Contents Table 3.15 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR(%), Market Share (%), 2019-2024 Table 3.16 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 3.17 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 4.1 Orion’s Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2018 Table 4.2 Orion’s Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024 Table 4.3 Teva’s Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2018 Table 4.4 Teva’s Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024 Table 4.5 UCB’s Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2018 Table 4.6 UCB’s Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024 Table 5.1 PD Market Breakdown by Region, Revenues ($m), Market Shares (%), 2012 Table 5.2 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.3 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 5.4 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 20132018 Table 5.5 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 20192024 Table 5.6 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 20132018 Table 5.7 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 20192024 Table 5.8 EU5 Regional Breakdown by Country, Revenues ($m), Market Share (%), 2012 Table 5.9 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.10 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 www.visiongain.com
  • 11. Contents Table 5.11 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.12 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 5.13 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.14 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 5.15 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 20132018 Table 5.16 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 20192024 Table 5.17 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.18 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 5.19 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.20 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 5.21 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.22 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 5.23 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 20132018 Table 5.24 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 20192024 Table 5.25 BRIC Regional Breakdown by Country, Revenues ($m), Market Shares (%), 2012 www.visiongain.com
  • 12. Contents Table 5.26 BRIC PD Drug Market Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.27 BRIC PD Drug Market Breakdown Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 5.28 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.29 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 5.30 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.31 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 5.32 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.33 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 5.34 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 Table 5.35 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 Table 6.1 Late-Stage PD Pipeline, 2013 Table 6.2 Reformulations of Levodopa and Other Dopaminergic Agents in Development, 2013 Table 6.3 Phase II PD Pipeline, 2013 Table 6.4 Glutamatergic PD Pipeline, 2013 Table 6.5 Early-Stage Developments for PD, 2013 Table 6.6 Selected Gene Therapies in the PD Pipeline, 2013 Table 7.1 Parkinson’s Disease Drug Market: Strengths and Weaknesses, 2014 Table 7.2 Parkinson’s Disease Drug Market: Opportunities and Threats, 2014-2024 Table 7.3 PD Drug Market: STEP Analysis, 2014 www.visiongain.com
  • 13. Contents List of Figures Figure 3.1 World PD Drug Market, Revenues ($m), 2012-2024 Figure 3.1 World PD Drug Market, Revenues ($m), 2012-2024 Figure 3.2 PD Market Segmentation ($m), Market Shares (%), 2012 Figure 3.3 PD Drug Market Breakdown by Segment, Revenues ($m), 2013-2024 Figure 3.4 PD Drug Market, Drivers and Restraints, 2014-2024 Figure 3.5 Dopaminergic Agents Segment Forecast, Revenues ($m), 2013-2024 Figure 3.6 Dopaminergic Agents Market: Drivers and Restraints, 2014-2024 Figure 3.7 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), 2013-2024 Figure 3.8 Dopamine Receptor Agonists Market, Drivers and Restraints, 2014-2024 Figure 3.9 COMT Inhibitors Segment Forecast, Revenues ($m), 2013-2024 Figure 3.10 COMT Inhibitors Market, Drivers and Restraints, 2014-2024 Figure 3.11 MAO Inhibitors Segment Forecast, Revenues ($m), 2013-2024 Figure 3.12 MAO Inhibitors Market, Drivers and Restraints, 2014-2024 Figure 3.13 Other Mechanisms of Action Segment Forecast, Revenues ($m), 2013-2024 Figure 3.14 Other Mechanisms of Action, Market Drivers and Restraints, 2014-2024 Figure 4.1 Revenues ($m) of Parkinson’s Drugs by Leading Company, 2010-2012 Figure 4.2 Orion’s Comtan/Stalevo Drug Revenues ($m) Forecast, 2013-2024 Figure 4.3 Teva’s Azilect Drug Revenues Forecast, 2013-2024 Figure 4.4 UCB’s Neupro Drug Revenues Forecast, 2013-2024 Figure 5.1 PD Market Breakdown by Region, Revenues ($m), Market Shares (%), 2012 Figure 5.2 PD Drug Market Breakdown by Region, Revenues ($m), 2013-2024 Figure 5.3 US Over-65 Population as Percentage of Overall Population, 2012-2024 Figure 5.4 US PD Drug Market, Revenue Forecast ($m), 2013-2024 Figure 5.5 EU5 PD Drug Market, Revenue ($m), 2013-2024 Figure 5.6 EU5 Regional Breakdown by Country, Revenues ($m), Market Share(%), 2012 Figure 5.7 EU5 Regional Breakdown by Country, Revenues ($m), 2013-2024 Figure 5.8 Over-65 Population in Germany as Percentage of Overall Population, 2012-2024 Figure 5.9 German PD Drug Market, Revenues ($m), 2013-2024 Figure 5.10 Over-65 Population in France as Percentage of Overall Population, 2012-2024 www.visiongain.com
  • 14. Contents Figure 5.11 French PD Drug Market, Revenues ($m), 2013-2024 Figure 5.12 Over-65 Population in the UK as a Percentage of Overall Population, 2013-2024 Figure 5.13 UK PD Drug Market, Revenues ($m), 2013-2024 Figure 5.14 Over-65 Population in Spain as Percentage of Overall Population, 2012-2024 Figure 5.15 Spanish PD Drug Market, Revenues ($m), 2013-2024 Figure 5.16 Over-65 Population in Italy as Percentage of Overall Population, 2012-2024 Figure 5.17 Italian PD Drug Market, Revenues ($m), 2013-2024 Figure 5.18: Over-65 Population in Japan as Percentage of Overall Population, 2012-2024 Figure 5.19 Japanese PD Drug Market, Revenues ($m), 2013-2024 Figure 5.20 BRIC PD Drug Market, Revenue ($m), 2012-2024 Figure 5.21 BRIC Regional Breakdown by Country, Revenues ($m), Market Share (%), 2012 Figure 5.22 BRIC PD Drug Market Breakdown, Revenues ($m), 2013-2024 Figure 5.23 Brazilian PD Drug Market, Revenues ($m), 2013-2024 Figure 5.24 Russian PD Drug Market, Revenues ($m), 2013-2024 Figure 5.25 Indian PD Drug Market, Revenues ($m), 2013-2024 Figure 5.26 Chinese PD Drug Market, Revenues ($m), 2013-2024 Figure 8.1 Parthenogenesis Results in Cells Inheriting a Duplicate Set of HLA genes, which Reduces Immune Rejection Figure 9.1 PD Drug Market, Overall Revenues ($m), 2012, 2018 and 2024 Figure 9.2 PD Drug Market by Segment, Revenues ($m), 2012, 2018 and 2024 www.visiongain.com
  • 15. Contents Organisations Mentioned in Report Abbott Laboratories AbbVie Pharmaceuticals Acadia Pharmaceuticals Adamas Pharmaceuticals Addex Therapeutics Amgen Amicus Therapeutics Amarantus BioSciences Amylin Pharmaceuticals Ark Therapeutics AstraZeneca Avanir Pharmaceuticals Axxonis Pharma BIAL - Portela Biogen Idec Bioprojet Pharma Biotie Therapies Biovail Boehringer Ingelheim Cardiovascular and Renal Drug Advisory Committee Ceregene Chelsea Therapeutics Civitas Therapeutics Columbia University Dainippon Sumitomo Pharma Depomed DiaGenic Domain Therapeutics Dr. Reddy’s Laboratories www.visiongain.com
  • 16. Contents Durin Technologies Eisai European Medicines Agency (EMEA/EMA) Food and Drug Administration (US FDA) Genzyme GlaxoSmithKline (GSK) Impax Laboratories Intec Pharma International Stem Cell Corporation Ipsen Juvantia Pharma Kyowa Hakko Kirin Lundbeck Meiji Seika Merck & Co. Merck Serono Mundipharma Research Mylan Napp Pharmaceuticals National Health Service (NHS, UK) National Institute for Health and Clinical Excellence (NICE, UK) National Institute of Neurological Disorders and Stroke (NINDS, US) National Institutes of Health (NIH, US) Neuren Pharmaceuticals Neuroderm NeuroGeneration NeuroHealing Neurologix Newron Pharmaceuticals Novartis www.visiongain.com
  • 17. Contents NuroPro Ono Pharmaceuticals Orient Pharma Orion Otsuka Pharmaceuticals Oxford BioMedica Parkinson’s UK Par Pharmaceuticals Pfizer Pharmaceutical Research and Manufacturers Association Phytopharm Power3 Medical Products Prothena Corporation Roche Roxane Laboratories Sanofi Santhera Schering Plough Sheffield Institute for Translational Neuroscience SK Biosciences Skye Pharma Sun Pharmaceuticals Technion-Israel Institute of Technology Teva Pharmaceutical Industries The Michael J. Fox Foundation The Parkinson Study Group Titan Pharmaceuticals UCB uniQure University College London (UCL) www.visiongain.com
  • 18. Contents Valeant Varinel Vectura Group Vernalis Watson Pharmaceuticals Wockhardt XenoPort Zambon Group www.visiongain.com
  • 19. Parkinson’s Disease: World Drug Industry and Market 2014-2024 5.6.5 India: Generic Manufacturers Seek to Dominate the PD Market The second largest country in the world with a population of 1.2 billon and an ageing population, India’s public healthcare system is overburdened. Most health care in India is presently provided by private sectors and therefore, there is a growing demand for unmet needs. A major challenge with India is the economic, population and perception issues. In April 2012, the rapid ageing of India was the focus of World Heath Day. India and China together have been reported to account for one third of the world’s total population over 65. With a growing population and rapid ageing, the incidence of old-age related diseases, such as PD is also bound to increase. Until the last five years, the incidence of PD was low in India but has slowly crept up in the last few years. Increasing health awareness has allowed the pharma market to drastically improve in the last five years. Similarly, the increase in awareness of PD will help boost the market. However, the issue of affordability is a huge factor. Like all emerging countries, India too is a generic market and therefore, the likes of Sun Pharma, Wockhardt, Dr. Reddy’s Laboratories, along with many other pharma companies, have produced generic PD products for the Indian population. Similar to all BRIC nations, the rise in middle-class spending power, government healthcare reforms and most importantly the increase in healthcare awareness has lead to a growth in the pharma market. Furthermore, India is believed to be a preferred partner of choice for many of the Big Pharma companies because of its formulation development capabilities, process chemistry expertise, skilled workforce and cheaper costs. In November 2012, The Indian Pharma Industry was valued at Rs 686bn, a 13% growth from the previous year. The Indian PD market alone is believed to have grown 24% in 2012, with similar numbers reported for the previous years. Thus, the market is expected to continue growing during this forecast period at rapid rate. Tables 5.32, 5.33 and Figure 5.25 show visiongain’s predictions for the Indian PD drug market over the forecast period. A continual gradual growth during the first half of the forecast period should see revenues of $35m by 2018 with a 6-year CAGR of 4.0%. The launch of new products in the market should see the market boost even further in the second half of the forecast period with revenues reaching $62m by 2024 (a 12-year CAGR of 7.0%), visiongain believes. www.visiongain.com Page 100
  • 20. Parkinson’s Disease: World Drug Industry and Market 2014-2024 Table 5.32 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018 BRIC India Revenues ($m) AGR (%) CAGR (%, 2012-2018) Market share (%) 2012 2013 2014 2015 2016 2017 2018 28 29 6 31 6 32 2 34 5 35 3 35 1 4.0 10.0 9.4 9.0 8.9 9.1 8.9 9.2 Source: visiongain 2014 Table 5.33 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024 BRIC 2019 2020 2021 2022 2023 2024 Revenues ($m) 45 48 52 55 59 62 AGR (%) 29 8 7 7 6 6 India CAGR (%, 2018-2024) 10.1 CAGR (%, 2012-2024) 7.0 Market share (%) 10.8 11.0 11.4 11.8 12.0 12.3 Source: visiongain 2014 Figure 5.25 Indian PD Drug Market, Revenues ($m), 2013-2024 70 60 Revenues ($m) 50 40 30 20 10 0 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Year Source: visiongain 2014 www.visiongain.com Page 101

×